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Abstract: Recently, many studies explored the role of inflammation
parameters in the prognosis of urinary cancers, but the results were not
consistent. The modified Glasgow Prognostic Score (mGPS), a systemic
inflammation marker, is a prognostic marker in various types of cancers.
The aim of the present study was to investigate the usefulness of theo, MD, PhD, Vinc MD, PhD,
uru Sonpavde, MD, and Daniela Terracciano, PhD
A total of 1037 patients with UBC were included in this study with a
median follow-up of 22 months (range 3–60 months). An mGPS¼ 0
was observed in 646 patients (62.3%), mGPS¼ 1 in 297 patients (28.6
%), and mGPS¼ 2 in 94 patients (9.1%).
In our study cohort, subjects with an mGPS equal to 2 had a
significantly shorter median RFS compared with subjects with mGPS
equal to 1 (16 vs 19 months, hazard ratio [HR] 1.54, 95% CI 1.31–1.81,
P< 0.001) or with subjects with mGPS equal to 0 (16 vs 29 months, HR
2.38, 95% CI 1.86–3.05, P< 0.001). The association between mGPS
and RFS was confirmed by weighted multivariate Cox model. Although
in univariate analysis higher mGPS was associated with lower OS and
CSS, this association disappeared in multivariate analysis where only
the presence of lymph node-positive bladder cancer and T4 stage were
predictors of worse prognosis for OS and CSS.
In conclusion, the mGPS is an easily measured and inexpensive
prognostic marker that was significantly associated with RFS in UBC
patients.
(Medicine 94(42):e1861)
Abbreviations: BCG = Bacillus Calmette–Guerin, BMI = body
mass index, CIS = carcinoma in situ, CRP = C-reactive protein,
CSS = cancer-specific survival, mGPS = modified Glasgow
prognostic score, NLR = neutrophil–lymphocyte ratio, OS =
overall survival, RC = radical cystectomy, RFS = recurrence-free
survival, TURBT = transurethral resection of the bladder tumor,
UBC = urothelial bladder cancer.
INTRODUCTION
W orldwide, urothelial bladder cancer (UBC) is the 7th mostfrequent cancer in men and the 17th most frequent cancer
in women, with annual mortality rates varying approximately in
the range of 1 to 5 deaths per 100,000 men and 0.5 to 1.5 deaths
per 100,000 women.1 Bladder cancer has been associated with a
number of factors, including smoking, occupational exposure,
pollution, as well as urinary calculi.1,2 Accurate prognostic
assessment after radical surgery, which is the mainstay ofdisease, is important to define indication
Multiple prognostic models with satis-
been proposed to evaluate the risk of
www.md-journal.com | 1
recurrence or death in bladder cancer patients, but not all the
variables included are readily measurable andmost models have
not been externally validated.4 Among the multitude of clinical,
pathological, radiological, and genetic variables of potential
clinical utility, serummarkers of systemic inflammation may be
particularly useful, because their intrinsic prognostic value is
coupled to the inexpensiveness, simplicity, and lack of inva-
siveness of their assessment.4 Systemic inflammation, which
has a detrimental effect in most solid tumors, can be measured
by assessing circulating myeloid-derived suppressor cells, neu-
trophil count, white cell count, neutrophil–lymphocyte ratio
(NLR), and C-reactive protein (CRP).5–7 The NLR measured at
the time of cystectomy is associated with overall and cancer-
specific mortality.7 CRP has an established prognostic role in
UBC8 and has been extensively investigated in a variety of
clinical settings, that is in patients undergoing transurethral
resection of the tumor,9 chemo-radiotherapy,10 or radical
cystectomy (RC)11–13 for loco-regional disease and in those
with advanced recurrent/systemic disease.14–16 This acute
phase response protein, which is released by hepatocytes in
response to inflammatory cytokines and also by tumor cells
themselves, can facilitate cancer cell survival by pleiotropic
effects and can be accurately measured in the serum.8 CRP has
been combined with albumin, which has an independent prog-
nostic value in patients undergoing RC for UBC,17 in order to
calculate the modified Glasgow Prognostic Score (mGPS), a
well-characterized scale with independent prognostic value in
various malignancies.18 As the clinical utility of the mGPS in
the particular case of UBC patients is yet to be extensively
explored,19 we aimed to investigate its prognostic value at the
time of RC in a large retrospective cohort of patients with
histologically confirmed UBC.
PATIENTS AND METHODS
Inclusion Criteria
Medical records of patients undergoing RC plus pelvic
lymphadenectomy between January 2008 and December 2013
at 8 Italian urologic centers (University of Naples ‘‘Federico
II’’; ‘‘Pascale’’ National Cancer Institute of Naples; European
Oncologic Institute, Milan; University of Bari ‘‘Aldo Moro’’;
University of Rome ‘‘La Sapienza’’; University of Salerno;
University of Catanzaro, Magna Graecia; and Humanitas
Clinical and Research Center, Milan) were reviewed. Patients
were included in this retrospective analysis if: they had histo-
logic diagnosis of UBC; they had not received any neoadjuvant
radiotherapy or chemotherapy; they did not present any infec-
tion or any other serious systemic inflammatory condition such
as ischemia, acute coronary syndrome, diabetes, and renal and
hepatic dysfunction at the time of surgery; and they had their
CRP and albumin levels assessed within 10 days before surgery.
Patients with pathological nonmuscle invasive disease at RC
were required to have received prior transurethral resection of
the bladder tumor (TURBT). The study has been approved by
local Ethics Committees and it conforms to the provisions of the
Declaration of Helsinki in 1995. Written informed consent to
take part was given by all participants.
Retrieved Data
Demographic data of eligible patients were retrieved along
Ferro et alwith anthropometric, clinical, and histologic characteristics
recorded at the time of surgery, and included the Eastern
Cooperative Oncology Group (ECOG) performance status,
2 | www.md-journal.combody mass index (BMI), smoking status, pathologic stage
and grade, metabolic syndrome, use of subsequent adjuvant
chemotherapy and prior endovesical chemotherapy, presence of
concomitant carcinoma in situ (CIS), CRP, and albumin levels.
Given the retrospective nature of this study, methods employed
for stage and grade assessment, as well as for CRP and albumin
levels determination were also retrieved.
Biochemical, Radiological, and Pathological
Assessment
All the institutions involved employed the 2009 tumor-
node-metastasis (TNM) staging and the 1973 WHO classifi-
cation for staging and grading assessment, respectively. Follow-
up was homogenous among all institutions involved, and was
planned for 5 years after surgery. It included physical examin-
ation, abdominal ultrasound, whole body CT scan with and
without contrast every 3 to 6 months. Other radiological assess-
ments, such as brain CT /MRI, were evaluated on an individual
basis.
Definition of the Modified GPS
The mGPS was computed as previously described.18
Briefly, the scores were assigned using the following criteria:
mGPS¼ 2 for patients with both an elevated CRP level
(>1.0 mg/dL) and hypoalbuminemia (<3.5 g/dL); mGPS¼ 1
for patients with only elevated CRP level (>1.0 mg/dL); for
patients with neither CRP nor albumin abnormalities it was
assigned a score of 0. Patients with normal CRP levels were
assigned an mGPS of 0, irrespective of the serum albumin level.
Statistical Methods
Descriptive analysis was based on median with range in
case of quantitative variables and on frequencies and percen-
tages in case of ordinal and categorical factors. Accordingly,
differences between mGPS risk groups were based on Krus-
kall–Wallis test or the Chi-squared test.
To evaluate the effect of mGPS on survival outcomes (recur-
rence-free [RFS], overall [OS], and cancer-specific [CSS] survival),
survival curves were generated by the Kaplan–Meier method and
compared by a log-rank test. To compare the prognostic accuracy of
mGPS versus CRP alone, time-dependent receiver operating
characteristic curve were used.
In order to adjust the analysis for potential confounding
effects and for known prognostic factors a Cox regression model
was initially planned; however, due to the violation of the
proportional hazard assumption, a weighted Cox regression
was applied to obtain unbiased average hazard ratio (HR)
estimates.20 Results of regression model were reported as
HRs with the corresponding 95% confidence intervals and P
values were based on the Wald test. All statistical tests were 2-
sided and P value <0.05 were considered to indicate statistical
significance.
R statistical software, version 3.2.0 (www.r-project.org),
was used for all statistical analyses.
RESULTS
Study Population
A total of 1037 patients who had received RC plus pelvic
lymphadenectomy were included in the study. Median age at the
Medicine  Volume 94, Number 42, October 2015time of surgery was 70 (range 42–88) years. A total of 676
patients (65.2%) had muscle-invasive disease, while 162
patients (15.6%) had concomitant in situ carcinoma. Positive
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinical Characteristics of the Study Population
mGPS
Overall Cohort (n¼ 1037) 0 (n¼ 646) 1 (n¼ 297) 2 (n¼ 94) P Value
Age
Median age in yr (range) 70 (42–88) 70 (42–88) 70 (43–88) 69.5 (49–87) 0.698
Age 60 yr, n (%) 834 (80.4) 516 (79.9) 238 (80.1) 80 (85.1) 0.485
Male gender 804 (77.5) 500 (77.4) 224 (75.2) 80 (85.1) 0.145
Body mass index (BMI)
Median BMI, kg/m2 (range) 25 (18–40) 25 (18–40) 25 (18–38) 27 (18–40) 0.061
BMI 30 kg/m2, n (%) 250 (24.1) 159 (24.6) 62 (20.9) 29 (30.9) 0.127
Smokers, n (%) 712 (68.7) 426 (65.9) 213 (71.7) 73 (77.7) 0.03
Pathologic stage (T), n (%) 0.198
Ta 108 (10.4) 69 (10.7) 30 (10.1) 9 (9.6)
T1 253 (24.4) 172 (26.6) 63 (21.2) 18 (19.1)
T2 452 (43.6) 277 (42.9) 135 (45.5) 40 (42.6)
T3 191 (18.4) 112 (17.3) 58 (19.5) 21 (22.3)
T4 33 (3.2) 16 (2.5) 11 (3.7) 6 (6.4)
Grade 0.001
1–2 115 (11.1) 76 (11.8) 29 (9.8) 10 (10.6)
3 922 (88.9) 570 (88.2) 268 (90.2) 84 (89.4)
Metabolic syndrome, n (%) 273 (26.3) 151 (23.4) 76 (25.6) 46 (48.9) <0.001
Nþ 266 (25.7) 142 (22.0) 84 (28.3) 40 (42.6) <0.001
Adjuvant chemotherapy 301 (29.1) 165 (25.5) 93 (31.3) 44 (46.8) <0.001
Endovesical chemotherapy, n (%) 498 (48.0) 332 (51.4) 133 (44.8) 33 (35.1) 0.005
Concomitant CIS 162 (15.6) 78 (12.1) 65 (21.9) 19 (20.2) <0.001
C-reactive protein (CRP)
Median CRP, mg/L (range) 7 (1–23)
CRP 10 mg/L 391 (37.7)
Albumin
Median albumin, g/L (range) 4.4 (2.6–5.8)
Albumin<3.5 g/L 97 (9.4)
ore.
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vant chemotherapy was administered in 301 patients (29.1%).
Metabolic syndrome was diagnosed in 273 patients (26.3%),
whereas median CRP and albumin levels were 7mg/L (range
1–23) and 4.4 g/L (range 2.6–5.8), respectively. An mGPS¼ 0
was observed in 646 patients (62.3%), mGPS¼ 1 in 297 patients
(28.6 %), and mGPS¼ 2 in 94 patients (9.1%).
Association Between mGPS and Clinical
Characteristics
Clinical characteristics of patients, stratified according to
mGPS, are showed in Table 1. HighermGPSwas associated with
smoking habit (P¼ 0.030), higher tumor grade (P¼ 0.001),
presence of metabolic syndrome (P< 0.001), lymph node-
positive bladder cancer (P< 0.001), use of adjuvant chemother-
apy (P< 0.001), absence of endovesical chemotherapy
(P¼ 0.005), and concomitant CIS (P< 0.001). Distribution of
age, gender, BMI, and pathological stage did not differ among
mGPS categories.
Prognostic Role of mGPS on RFS, OS, and CSS
During a median follow-up of 22 months (range 3–60
CIS ¼ carcinoma in situ; mGPS ¼ modified Glasgow Prognostic Scmonths), a total of 780 subjects (71.8%) experienced a recur-
rence of disease. The median RFS time was 23 months (range
21–25 months).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.In univariate analyses, the mGPS was significantly associ-
ated with RFS. In particular subjects with an mGPS equal to 2
had a significantly shorter median RFS compared with subjects
with mGPS equal to 1 (16 vs 19months, HR 1.54, 95%CI 1.31–
1.81; P< 0.001) or with subjects with mGPS equal to 0 (16 vs
29 months, HR 2.38, 95% CI 1.86–3.05; P< 0.001). The log-
rank Chi-squared statistics for trend was equal to 64.6
(P< 0.001; Fig. 1). The 5-year RFS rates for patients with
an mGPS of 0, 1, and 2 were 36% (95%CI 32–40), 18%
(95%CI 14–23), and 5% (95%CI 2–14), respectively. When
comparing the prognostic accuracy of mGPS versus CRP alone
using time-dependent ROC curve analysis, it emerged that
mGPS was superior to CRP for predicting a recurrence of
disease during the whole follow-up period but the first year
(Table 2).
The association between mGPS and RFS was confirmed in
weighted multivariable Cox model (Table 3). In particular
subjects with mGPS equal to 1, had an hazard of recurrence
in the first 5 years, 1.2 times higher than subjects with mGPS
equal to 0 (95%CI 1.10–1.43; P¼ 0.024). The hazard became
even higher in case of mGPS equal to 2 (HR 1.55, 95%CI 1.22–
1.98; P< 0.001). The other variables that remained predictive
of a poorer RFS were increasing age, higher BMI, smoking
habit, pathological stage greater than T1, grade 2 or 3, and
lymph node-positive bladder cancer.
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Ferro et alAlthough in univariate analysis higher mGPS was associ-
ated with lower OS and CSS (Figs. 2 and 3), this finding was not
confirmed at multivariate analysis, which showed that only
positive lymph node and T4 stage were predictors of worse
prognosis for OS and CSS (Table 3).
DISCUSSION
The effectiveness of intravesical Bacillus Calmette–
Guerin (BCG) shows that local inflammatory responses are
essential for control/eradication of UBC,21 which is consistent
with the association of immunosuppression with bladder can-
cer.22 Conversely, systemic inflammation is detrimental in
bladder cancer patients. Nonsteroidal anti-inflammatory medi-
cations reduce the risk of UBC, similarly to dietary flavonoids,
which have anti-inflammatory and anti-oxidant properties.23–25
Among the markers of systemic inflammation, CRP has been
extensively investigated in UBC patients undergoing RC. In a
retrospective study by Sejima et al13 involving 249 consecutive
UBC patients treated with RC without neoadjuvant therapy,
a positive surgical margin, high CRP (>0.5mg/dL), low
FIGURE 1. Kaplan–Meier Curve: Preoperative mGPS and RFS in
patients with UBC. mGPS ¼ modified Glasgow Prognostic Score;
RFS ¼ recurrence-free survival; UBC ¼ urothelial bladder cancer.hemoglobin (<10.5mg/dL), and extravesical T stage (pT3a)
pT3a) were independent predictors of poor disease-specific
survival. These variables were combined in a risk-group
TABLE 2. Areas Under the Curve Associated With RFS Using mG
Areas Under the Curve
12 mo 24 mo
mGPS 53.14 (49.44; 56.84) 59.29 (56.36; 62.22) 62.92
CRP 51.33 (47.02; 55.64) 53.77 (50.21; 57.34) 56.94
P Value 0.141 <0.001
CRP ¼ C-reactive protein; mGPS ¼ modified Glasgow Prognostic Scor
4 | www.md-journal.comclassification model, with patients classified at low, intermedi-
ate, and high risk showing a 2/4-year disease-specific survival
of 88.0/77.7%, 42.1/23.6%, and 22.1/7.4%, respectively. In the
retrospective study by Gakis et al11 involving 246 patients
undergoing RC for UBC, the 3-year CSS was significantly
higher in patients with normal versus elevated CRP (74% vs
44.0%). Elevated CRP, tumor stage, resection margin status,
and lymph node density (P¼ 0.02) were independent predictors
of CSS. Of note, CRP increased the model predictive accuracy
by 4.9% with a concordance index of the final model of 0.788
(P¼ 0.01). A larger retrospective study was conducted by Viers
et al,7 who analyzed the prognostic role of preoperative NLR in
899 patients undergoing RC, and found that the NLR was
associated with greater risks of disease recurrence (HR 1.04;
P¼ 0.02), bladder cancer-specific mortality (HR 1.04;
P¼ 0.01), and all-cause mortality (HR 1.03; P¼ 0.01). Inter-
estingly, the NLR was also associated with a more advanced
pathologic stage (approximately 68% vs 56% of patients with
T2 disease had an NLR<2.7 vs>2.7 and approximately 32%
vs 44% of patients with >T2 disease had an NLR <2.7 vs
>2.7). This result is consistent with those obtained in the series
by Sejima et al13 and Gakis et al,11 which concordantly indicate
that levels of CRP are associated with a more advanced disease
stage. In our cohort of 1037 patients, we aimed to measure
systemic inflammation by using the mGPS, rather than CRP
alone. The incorporation of CRP and albumin levels allow to
take into account the effects of systemic inflammation and the
progressive nutritional decline associated with advanced can-
cer. We found that a modified mGPS of 1 or 2 (vs 0) was,
respectively, associated with a 29% or 79% increase in the HR
of recurrence, whereas we did not identify any association of the
mGPS with T stage. Unlike the other mentioned studies, we
failed to identify any association of the mGPS with OS or CSS
at multivariate analysis. This may simply be related to the short
follow-up time in a population with no evidence of disease after
surgery, with many censored patients at the time of the survival
analysis. Interestingly, we found that the mGPS was associated
with in situ carcinoma. We found that incidence of in situ
carcinoma was approximately double in patients with an mGPS
of 1 to 2 versus 0 (21% vs 12%). The diagnosis of in situ
carcinoma is elusive and it relies on clinical suspicion (which
has low accuracy), urine cytology (which has low sensitivity),
and photodynamic diagnosis (which is not universally avail-
able).2 Pending confirmation in adequately designed studies,
the mGPS may help identify those patients who are at increased
risk of in situ carcinoma and may benefit from diagnostic
random bladder biopsies.
Our study has a number of limitations. Its retrospective and
Medicine  Volume 94, Number 42, October 2015multicenter nature did not allow to adjust the results obtained
for the different surgeons’ experience and preferences, as well
as for different follow-up schedule and adjuvant chemotherapy
PS vs CRP Alone at 12, 24, 36, 48, and 60 Months
With 95% Confidence Interval
36 mo 48 mo 60 mo
(60.13; 65.71) 63.41 (60.58; 66.24) 63.29 (60.47; 66.11)
(53.4; 60.48) 57.51 (53.89; 61.14) 57.51 (53.9; 61.13)
<0.001 <0.001 <0.001
e; RFS ¼ recurrence-free survival.
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TABLE 3. Multivariable Cox Model Showing the Association Between Modified Glasgow Prognostic Score (mGPS) and
Recurrence-Free Survival (RFS), Overall Survival (OS), and Cancer-Specific Survival (CSS)
RFS OS CSS
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
mGPS (0 ref.)
0 1.00 1.00 1.00
1 1.20 (1.10–1.43) 0.024 1.19 (0.84–1.70) 0.332 0.87 (0.54–1.40) 0.565
2 1.55 (1.22–1.98) <0.001 1.25 (0.74–2.11) 0.410 0.94 (0.49–1.81) 0.853
Age 1.01 (1.00–1.02) 0.007 1.00 (0.99–1.02) 0.739 1.01 (0.99–1.04) 0.288
BMI 1.02 (1.01–1.04) 0.006 0.99 (0.96–1.03) 0.664 1.03 (0.99–1.07) 0.164
Smoking 1.39 (1.17–1.64) <0.001 0.96 (0.66–1.40) 0.830 0.85 (0.52–1.39) 0.522
Pathologic stage
Ta 1.00 1.00 1.00
T1 1.06 (0.75–1.51) 0.731 1.52 (0.50–4.63) 0.458 1.39 (0.18–10.79) 0.751
T2 2.53 (1.84–3.48) <0.001 2.72 (0.96–7.70) 0.060 6.17 (0.87–43.58) 0.068
T3 3.18 (2.16–4.69) <0.001 2.69 (0.95–7.64) 0.062 4.2 (0.61–28.80) 0.144
T4 2.96 (1.62–5.42) <0.001 12.54 (3.94–39.97) <0.001 32.23 (3.98–260.99) 0.001
Grade
1–2 1.00 1.00 1.00
3 2.39 (1.62–3.55) <0.001 2.85 (0.92–8.80) 0.069 4.64 (0.65–33.10) 0.126
Metabolic syndrome 0.78 (0.56–1.08) 0.098 1.16 (0.80–1.66) 0.436 1.07 (0.68–1.70) 0.768
Endovesical chemotherapy 0.88 (0.74–1.04) 0.141 0.76 (0.54–1.08) 0.132 0.83 (0.54–1.30) 0.424
Nþ 8.67 (5.53–13.61) <0.001 5.42 (2.28–12.86) <0.001 6.1 (1.90–19.58) 0.002
Adjuvant chemotherapy 0.61 (0.37–1.01) 0.052 1.58 (0.62–4.01) 0.340 3.75 (1.00–13.49) 0.049
CIS 1.21 (0.97–1.51) 0.097 0.87 (0.56–1.37) 0.560 0.97 (0.53–1.77) 0.910
a in
Medicine  Volume 94, Number 42, October 2015 Modified Glasgow Prognostic Score in Bladder Cancerindications. Furthermore, a central pathology review was not
performed, nor we did not collect data regarding other estab-
BMI ¼ body mass index; CI ¼ confidence interval; CIS ¼ carcinomlished markers of systemic inflammation, such as hemoglobin
levels and the NLR. The relative prognostic value of these
biomarkers was not assessed in the multivariate analysis.
FIGURE 2. Kaplan–Meier Curve: Preoperative mGPS and OS in
patients with UBC. mGPS ¼ modified Glasgow Prognostic Score;
OS ¼ overall survival; UBC ¼ urothelial bladder cancer.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Nevertheless, it must be noted that this is the largest cohort
of bladder cancer patients ever assessed for a systemic inflam-
situ; HR ¼ hazard ratio.mation biomarker, and includes a large proportion of patients
with Ta–T1 disease, so the results achieved can be generalized
to patients with any stage of the disease. Our study adds
FIGURE 3. Kaplan–Meier Curve: Preoperative mGPS and CSS in
patients with UBC. mGPS ¼ modified Glasgow Prognostic Score;
CSS ¼ cancer-specific survival; UBC ¼ urothelial bladder cancer.
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evidence to the growing body of literature on the prognostic role
of the systemic markers of inflammation. We suggest that
mGPS should be explored in prospective clinical trials in order
to improve timing of cystectomy in T1 patients, indication of
adjuvant chemotherapy in T2 patients, indication for random
biopsies to detect CIS.
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